Edwyn

Edwyn Search SEC Edgar companies...⌘K

Investing IdeasCompare Stocks

NVDA TSLA AAPL

Overview

ValuationValuation Calculator Relative Valuation Intrinsic Value (DCF)

FinancialsIncome Statement Balance Sheet Cash Flow

Explore Demo

Relative Valuation

ALNY Relative Valuation

Compare public peers against market pricing to see what the current peer set implies for fair value.

Adjust Assumptions

Peer Assumption Controls

Adjust the usable peer mix to instantly see how different valuation multiples impact the blended fair value.

Peer-Implied Fair Value

$136.34

Blended value per share

Peers imply 42.5% downside

Weighting Mixer

EV / EBITDA

34%

Price / Sales

33%

Price / Earnings

33%

Value Contribution Breakdown

EV / EBITDA

Implied peer value: $14.17B

$4.82B34% Weight

Price / Sales

Implied peer value: $40.41B

$13.33B33% Weight

Price / Earnings

Implied peer value: $273.85M

$90.37M33% Weight

5 PeersView Full Peer Table

Equal-Weight Baseline

Discount 0.2% vs Base

$18.28B

This represents the simple average of all usable peer methods before your custom weighting adjustments are applied.

Base fair value / share:$136.65

Intrinsic Cross-Check

Underwrite Your Own Assumptions

Move beyond relative peer pricing. Use intrinsic valuation when you want to underwrite precise cash-flow forecasts, discount rates, and complex scenario ranges.

Open Intrinsic Model

Spreadsheet Data

Underlying Peer Data

Audit the saved peer set and the method inputs behind the blended fair value.

Peer data table

Review the saved peer set across price, scale, operating metrics, and raw valuation multiples.

Peer	Price	Market Cap	Enterprise Value	Revenue

Adjust Assumptions

Peer Assumption Controls

Adjust the usable peer mix to instantly see how different valuation multiples impact the blended fair value.

Peer-Implied Fair Value

$136.34

Blended value per share

Peers imply 42.5% downside

Weighting Mixer

EV / EBITDA

34%

Price / Sales

33%

Price / Earnings

33%

Value Contribution Breakdown

EV / EBITDA

Implied peer value: $14.17B

$4.82B34% Weight

Price / Sales

Implied peer value: $40.41B

$13.33B33% Weight

Price / Earnings

Implied peer value: $273.85M

$90.37M33% Weight

5 PeersView Full Peer Table

Equal-Weight Baseline

Discount 0.2% vs Base

$18.28B

This represents the simple average of all usable peer methods before your custom weighting adjustments are applied.

Base fair value / share:$136.65

Intrinsic Cross-Check

Underwrite Your Own Assumptions

Move beyond relative peer pricing. Use intrinsic valuation when you want to underwrite precise cash-flow forecasts, discount rates, and complex scenario ranges.

Open Intrinsic Model

Spreadsheet Data

Underlying Peer Data

Audit the saved peer set and the method inputs behind the blended fair value.

Peer data table

Review the saved peer set across price, scale, operating metrics, and raw valuation multiples.

Peer	Price	Market Cap	Enterprise Value	Revenue

Weighted Averages

See which peer averages feed the weighted fair value and which methods are excluded.

Method	Type	Avg. Multiple	Coverage	Implied Equity Value	Fair Value / Share	Status
EV / EBITDA EVActive	Enterprise Multiple	31.01x	2/5	$14.17B	$105.93	Included in the active peer mix.
Price / Sales PSActive	Equity Multiple	10.88x	5/5	$40.41B	$301.96	Included in the active peer mix.
Price / Earnings PEActive	Equity Multiple	0.87x	5/5	$273.85M	$2.05	Included in the active peer mix.

Peer data table

Open the saved peer table used to audit the fair value view.

Peer	Price	Market Cap	Enterprise Value	Revenue	EBITDA	Net Income	P/E	P/S	EV/EBITDA
MR MRNA Moderna, Inc. FY ended Feb 13, 2026	$137.99	$55.09B	$54.81B	$1.94B	-$2.76B	-$2.82B	-19.01x	28.34x	—
SR SRPT Sarepta Therapeutics, Inc. FY ended Feb 24, 2026	$20.86	$2.20B	$2.78B	$2.20B	-$686.34M	-$713.41M	-2.93x	1.00x	—
VR VRTX VERTEX PHARMACEUTICALS INC / MA FY ended Feb 06, 2026	$541.69	$137.30B	$134.75B	$12.00B	$4.88B	$3.95B	35.36x	11.44x	27.38x
BN BNTX BioNTech SE FY ended Mar 27, 2026	$102.08	$25.64B	$20.65B	$2.87B	-$1.12B	-$1.14B	-21.72x	8.93x	—
AC ACAD ACADIA PHARMACEUTICALS INC FY ended Feb 18, 2026	$29.11	$5.02B	$5.09B	$1.07B	$150.66M	$391.00M	12.66x	4.68x	33.81x

Weighted Averages

Open the peer-average inputs behind the weighted result.

Method	Type	Avg. Multiple	Coverage	Implied Equity Value	Fair Value / Share	Status
EV / EBITDA EVActive	Enterprise Multiple	31.01x	2/5	$14.17B	$105.93	Included in the active peer mix.
Price / Sales PSActive	Equity Multiple	10.88x	5/5	$40.41B	$301.96	Included in the active peer mix.
Price / Earnings PEActive	Equity Multiple	0.87x	5/5	$273.85M	$2.05	Included in the active peer mix.